

MD Anderson Ovarian SPORE publications – 2021

1. Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LMS, Jiang M, Raso MG, Wang S, Bell D, Liu J, Wang H, Tan D, Torres-Cabala C, Gan Q, Wu Y, Albarracin C, Hung MC, Meric-Bernstam F, Wistuba II, Prieto VG, Sahin AA, Ding Q. **TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer.** *Mod Pathol.* 2021 Apr;34(4):710-719. doi: 10.1038/s41379-020-00692-8. Epub 2020 Oct 3. PMID: 33011748.
2. Alvarez Secord A, O'Malley DM, Sood AK, Westin SN, Liu JF. **Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.** *Gynecol Oncol.* 2021 Aug;162(2):482-495. doi: 10.1016/j.ygyno.2021.05.018. Epub 2021 Jun 3. PMID: 34090705
Review.
3. Amero P, Lokesh GLR, Chaudhari RR, Cardenas-Zuniga R, Schubert T, Attia YM, Montalvo-Gonzalez E, Elsayed AM, Ivan C, Wang Z, Cristini V, Franciscis V, Zhang S, Volk DE, Mitra R, Rodriguez-Aguayo C, Sood AK, Lopez-Berestein G. **Conversion of RNA Aptamer into Modified DNA Aptamers Provides for Prolonged Stability and Enhanced Antitumor Activity.** *J Am Chem Soc.* 2021 May 26;143(20):7655-7670. doi: 10.1021/jacs.9b10460. Epub 2021 May 14. PMID: 33988982.
4. Bailey CD, Previs R, Fellman BM, Zaid T, Huang M, Brown A, Enbaya A, Balakrishnan N, Broaddus RR, Bodurka DC, Soliman P, Fleming ND, Nick A, Sood AK, Westin SN. **Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer.** *Int J Gynecol Cancer.* 2021 Feb;31(2):232-237. doi: 10.1136/ijgc-2020-001597. Epub 2020 Oct 29. PMID: 33122243. PMCID: PMC8263077.
5. Bindra S, McGill MA, Triplett MK, Tyagi A, Thaker PH, Dahmouh L, Goodheart MJ, Ogden RT, Owusu-Ansah E, R Karan K, Cole S, Sood AK, Lutgendorf SK, Picard M. **Mitochondria in epithelial ovarian carcinoma exhibit abnormal phenotypes and blunted associations with biobehavioral factors.** *Sci Rep.* 2021 Jun 2;11(1):11595. doi: 10.1038/s41598-021-89934-6. PMID: 34078919. PMCID: PMC8172869.
6. Chang CM, Li YF, Lin HC, Lu KH, Lin TW, Liu LC, Su KM, Chang CC. **Dysregulated Immunological Functionome and Dysfunctional Metabolic Pathway Recognized for the Pathogenesis of Borderline Ovarian Tumors by Integrative Polygenic Analytics.** *Int J Mol Sci.* 2021 Apr 15;22(8):4105. doi: 10.3390/ijms22084105. PMID: 33921111. PMCID: PMC8071470.
7. Cho MS, Li J, Gonzalez-Delgado R, Lee H, Vasquez M, He T, He Y, Liu K, Sasano T, Nürnberg B, Sood AK, Wong STC, Afshar-Kharghan V. **The effect of platelet G proteins on platelet extravasation and tumor growth in the murine model of ovarian cancer.** *Blood Adv.* 2021 Apr 13;5(7):1947-1951. doi: 10.1182/bloodadvances.2020003410. PMID: 33821990. PMCID: PMC8045495.
8. Cuneo MG, Szeto A, Schrepf A, Thaker PH, Goodheart M, Cole SW, Sood AK, McCabe PM, Mendez AJ, Lutgendorf SK. **Positive Psychosocial Factors and Oxytocin in the Ovarian Tumor Microenvironment.** *Psychosom Med.* 2021 Jun 1;83(5):417-422. doi: 10.1097/PSY.0000000000000935. PMID: 34080583. PMCID: PMC8175871.
9. Dottino JA, Zhang Q, Loose DS, Fellman B, Melendez BD, Borthwick MS, McKenzie LJ, Yuan Y, Yang RK, Broaddus RR, Lu KH, Soliman PT, Yates MS. **Endometrial biomarkers in premenopausal women with obesity: an at-risk cohort.** *Am J Obstet Gynecol.* 2021 Mar;224(3):278.e1-278.e14. doi: 10.1016/j.ajog.2020.08.053. Epub 2020 Aug 21. PMID: 32835719. PMCID: PMC7897335.
10. Elsayed AM, Bayraktar E, Amero P, Salama SA, Abdelaziz AH, Ismail RS, Zhang X, Ivan C, Sood AK, Lopez-Berestein G, Rodriguez-Aguayo C. **PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway.** *Int J Mol Sci.* 2021 Feb 13;22(4):1882. doi: 10.3390/ijms22041882. PMID: 33668685. PMCID: PMC7918312.

11. Fahrman JF, Irajizad E, Kobayashi M, Vykoukal J, Dennison JB, Murage E, Wu R, Long JP, Do KA, Celestino J, Lu KH, Lu Z, Bast RC, Hanash S. **A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer.** *Cancers (Basel)*. 2021 Feb 22;13(4):913. doi: 10.3390/cancers13040913. PMID: 33671595. PMCID: PMC7927060.
12. Fleming ND, Westin SN, Meyer LA, Shafer A, Rauh-Hain JA, Onstad M, Cobb L, Bevers M, Fellman BM, Burzawa J, Bhosale P, Zand B, Jazaeri A, Levenback C, Coleman RL, Soliman PT, Sood AK. **Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer.** *Int J Gynecol Cancer*. 2021 Jan;31(1):92-97. doi: 10.1136/ijgc-2020-001718. Epub 2020 Nov 5. PMID: 33154095. PMCID: PMC8266398.
13. Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH, Sood AK. **Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.** *Gynecol Oncol*. 2021 Jul;162(1):65-71. doi: 10.1016/j.ygyno.2021.04.002. Epub 2021 Apr 7. PMID: 33838925. PMCID: PMC8287765.
14. Garvin L, Slavich GM, Schrepf A, Davis LZ, Thaker PH, Goodheart MJ, Cole SW, Sood AK, Lutgendorf SK. **Chronic difficulties are associated with poorer psychosocial functioning in the first year post-diagnosis in epithelial ovarian cancer patients.** *Psychooncology*. 2021 Jun;30(6):954-961. doi: 10.1002/pon.5682. Epub 2021 Apr 1. PMID: 33760306. PMCID: PMC8178235.
15. Glubb DM, Thompson DJ, Aben KKH, Alsulimani A, Amant F, Annibali D, Attia J, Barricarte A, Beckmann MW, Berchuck A, Bermisheva M, Bernardini MQ, Bischof K, Bjorge L, Bodelon C, Brand AH, Brenton JD, Brinton LA, Bruinsma F, Buchanan DD, Burghaus S, Butzow R, Cai H, Carney ME, Chanock SJ, Chen C, Chen XQ, Chen Z, Cook LS, Cunningham JM, De Vivo I, deFazio A, Doherty JA, Dörk T, du Bois A, Dunning AM, Dürst M, Edwards T, Edwards RP, Ekici AB, Ewing A, Fasching PA, Ferguson S, Flanagan JM, Fostira F, Fountzilas G, Friedenreich CM, Gao B, Gaudet MM, Gawelko J, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harris HR, Harter P, Hein A, Heitz F, Hildebrandt MAT, Hillemanns P, Høgdall E, Høgdall CK, Holliday EG, Huntsman DG, Huzarski T, Jakubowska A, Jensen A, Jones ME, Karlan BY, Karnezis A, Kelley JL, Khusnutdinova E, Killeen JL, Kjaer SK, Klapdor R, Köbel M, Konopka B, Konstantopoulou I, Kopperud RK, Koti M, Kraft P, Kupryjanczyk J, Lambrechts D, Larson MC, Le Marchand L, Lele S, Lester J, Li AJ, Liang D, Liebrich C, Lipworth L, Lissowska J, Lu L, Lu KH, Macciotta A, Mattiello A, May T, McAlpine JN, McGuire V, McNeish IA, Menon U, Modugno F, Moysich KB, Nevanlinna H, Odunsi K, Olsson H, Orsulic S, Osorio A, Palli D, Park-Simon TW, Pearce CL, Pejovic T, Permuth JB, Podgorska A, Ramus SJ, Rebbeck TR, Riggan MJ, Risch HA, Rothstein JH, Runnebaum IB, Scott RJ, Sellers TA, Senz J, Setiawan VW, Siddiqui N, Sieh W, Spiewankiewicz B, Sutphen R, Swerdlow AJ, Szafron LM, Teo SH, Thompson PJ, Thomsen LCV, Titus L, Tone A, Tumino R, Turman C, Vanderstichele A, Edwards DV, Vergote I, Vierkant RA, Wang Z, Wang-Gohrke S, Webb PM; OPAL Study Group; AOCs Group, White E, Whittemore AS, Winham SJ, Wu X, Wu AH, Yannoukakos D, Spurdle AB, O'Mara TA. **Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers.** *Cancer Epidemiol Biomarkers Prev*. 2021 Jan;30(1):217-228. doi: 10.1158/1055-9965.EPI-20-0739. Epub 2020 Nov 3. PMID: 33144283.
16. Harrison RF, Cantor SB, Sun CC, Villanueva M, Westin SN, Fleming ND, Toumazis I, Sood AK, Lu KH, Meyer LA. **Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.** *Gynecol Oncol*. 2021 Apr;161(1):56-62. doi: 10.1016/j.ygyno.2021.01.024. Epub 2021 Jan 31. PMID: 33536126. PMCID: PMC8247119.
17. Harrison RF, Fu S, Sun CC, Zhao H, Lu KH, Giordano SH, Meyer LA. **Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer.** *Am J Obstet Gynecol*. 2021 Jul;225(1):68.e1-68.e11. doi: 10.1016/j.ajog.2021.01.029. Epub 2021 Feb 4. PMID: 33549538. PMCID: PMC8254740.

18. Hashemi Sheikhshabani S, Amini-Farsani Z, Rahmati S, Jazaeri A, Mohammadi-Samani M, Asgharzade S. **Oleuropein reduces cisplatin resistance in ovarian cancer by targeting apoptotic pathway regulators.** *Life Sci.* 2021 Aug 1;278:119525. doi: 10.1016/j.lfs.2021.119525. Epub 2021 Apr 21. PMID: 33894272
19. Hinchcliff E, Chelariu-Raicu A, Westin SN. **Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance.** *Curr Opin Obstet Gynecol.* 2021 Feb 1;33(1):19-25. doi: 10.1097/GCO.0000000000000678. PMID: 33315700. PMCID: PMC7958870.
20. Hong B, Chapa V, Saini U, Modgil P, Cohn DE, He G, Siddik ZH, Sood AK, Yan Y, Selvendiran K, Pei G, Zhao Z, Yoo JY, Kaur B. **Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity.** *Clin Cancer Res.* 2021 Jan 15;27(2):542-553. doi: 10.1158/1078-0432.CCR-20-2210. Epub 2020 Oct 21. PMID: 33087329. PMCID: PMC8147278.
21. How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A. **The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial.** *Invest New Drugs.* 2021 Jun;39(3):829-835. doi: 10.1007/s10637-020-01043-9. Epub 2021 Jan 7. PMID: 33415580. PMCID: PMC8076052.
22. How JA, Jazaeri AA, Fellman B, Daniels MS, Penn S, Solimeno C, Yuan Y, Schmeler K, Lanchbury JS, Timms K, Lu KH, Yates MS. **Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.** *Cancers (Basel).* 2021 Feb 24;13(5):946. doi: 10.3390/cancers13050946. PMID: 33668244. PMCID: PMC7956737.
23. Huang T, Fu X, Wang N, Yang M, Zhang M, Wang B, Chen T, Majaz S, Wang H, Wong CW, Liu J, Guan M. **Andrographolide prevents bone loss via targeting estrogen-related receptor- α -regulated metabolic adaption of osteoclastogenesis.** *Br J Pharmacol.* 2021 Jul 7. doi: 10.1111/bph.15614. PMID: 34233019
24. Hunt AL, Bateman NW, Barakat W, Makohon-Moore S, Hood BL, Conrads KA, Zhou M, Calvert V, Pierobon M, Loffredo J, Litzi TJ, Oliver J, Mitchell D, Gist G, Rojas C, Blanton B, Robinson EL, Odunsi K, Sood AK, Casablanca Y, Darcy KM, Shriver CD, Petricoin EF, Rao UNM, Maxwell GL, Conrads TP. **Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens.** *iScience.* 2021 Jun 21;24(7):102757. doi: 10.1016/j.isci.2021.102757. eCollection 2021 Jul 23. PMID: 34278265. PMCID: PMC8264160.
25. Kamat AA, Fletcher M, Gruman LM, Mueller P, Lopez A, Landen CN Jr, Han L, Gershenson DM, Sood AK. **Editor's Note: The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer.** *Clin Cancer Res.* 2021 Aug 1;27(15):4455. doi: 10.1158/1078-0432.CCR-21-2121. PMID: 34341060.
26. Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MMK, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AK. **Editor's Note: Functional Roles of *Src* and *Fgr* in Ovarian Carcinoma.** *Clin Cancer Res.* 2021 Aug 1;27(15):4452. doi: 10.1158/1078-0432.CCR-21-2118. PMID: 34341057.
27. Lee S, Zhao L, Little LD, Westin SN, Jazarei AA, Fleming ND, Zhang J, Futreal PA, Sood AK. **Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups.** *iScience.* 2021 Jan 9;24(2):102053. doi: 10.1016/j.isci.2021.102053. eCollection 2021 Feb 19. PMID: 33537658. PMCID: PMC7840469.
28. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MMK, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. **Editor's Note: Therapeutic Targeting of**

ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2021 Aug 1;27(15):4454. doi: 10.1158/1078-0432.CCR-21-2120. PMID: 34341059.

29. Matsuo K, Matsuzaki S, Nusbaum DJ, Maoz A, Oda K, Klar M, Roman LD, Sood AK. **Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.** Gynecol Oncol. 2021 Jan;160(1):32-39. doi: 10.1016/j.ygyno.2020.10.027. Epub 2020 Oct 24. PMID: 33196436.
30. Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MMK, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK. **Editor's Note: Targeting Src in Mucinous Ovarian Carcinoma.** Clin Cancer Res. 2021 Aug 1;27(15):4450. doi: 10.1158/1078-0432.CCR-21-2116. PMID: 34341055.
31. Mitra A, Yoshida-Court K, Solley TN, Mikkelson M, Yeung CLA, Nick A, Lu K, Klopp AH. **Extracellular vesicles derived from ascitic fluid enhance growth and migration of ovarian cancer cells.** Sci Rep. 2021 Apr 28;11(1):9149. doi: 10.1038/s41598-021-88163-1. PMID: 33911091. PMCID: PMC8080718.
32. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. **ATP11B mediates platinum resistance in ovarian cancer.** J Clin Invest. 2021 Apr 1;131(7):e149893. doi: 10.1172/JCI149893. PMID: 33792569. Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LMS, Jiang M, Raso MG, Wang S, Bell D, Liu J, Wang H, Tan D, Torres-Cabala C, Gan Q, Wu Y, Albarracin C, Hung MC, Meric-Bernstam F, Wistuba II, Prieto VG, Sahin AA, Ding Q. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol. 2021 Apr;34(4):710-719. doi: 10.1038/s41379-020-00692-8. Epub 2020 Oct 3. PMID: 33011748. PMCID: PMC8011885.
33. Moreno-Smith M, Lu C, Shahzad MMK, Pena GNA, Allen JK, Stone RL, Mangala LS, Han HD, Kim HS, Farley D, Berestein GL, Cole SW, Lutgendorf SK, Sood AK. **Editor's Note: Dopamine Blocks Stress-mediated Ovarian Carcinoma Growth.** Clin Cancer Res. 2021 Aug 1;27(15):4451. doi: 10.1158/1078-0432.CCR-21-2117. PMID: 34341056.
34. Nitecki R, Fleming ND, Fellman BM, Meyer LA, Sood AK, Lu KH, Rauh-Hain JA. **Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer.** Gynecol Oncol. 2021 Jun;161(3):660-667. doi: 10.1016/j.ygyno.2021.04.012. Epub 2021 Apr 16. PMID: 33867146. PMCID: PMC8165031.
35. Nitecki R, Moss HA, Watson CH, Urbauer DL, Melamed A, Lu KH, Lipkin SM, Offit K, Rauh-Hain JA, Frey MK. **Facilitated cascade testing (FaCT): a randomized controlled trial.** Int J Gynecol Cancer. 2021 May;31(5):779-783. doi: 10.1136/ijgc-2020-002118. Epub 2020 Dec 18. PMID: 33443030.
36. Niu N, Shen W, Zhong Y, Bast RC Jr, Jazaeri A, Sood AK, Liu J. **Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.** Hum Pathol. 2021 Jul;113:20-27. doi: 10.1016/j.humpath.2021.04.003. Epub 2021 Apr 19. PMID: 33887301. PMCID: PMC8219231.
37. Noh K, Bach DH, Choi HJ, Kim MS, Wu SY, Pradeep S, Ivan C, Cho MS, Bayraktar E, Rodriguez-Aguayo C, Dasari SK, Stur E, Mangala LS, Lopez-Berestein G, Sood AK. **The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis.** Oncogene. 2021 Jan;40(2):384-395. doi: 10.1038/s41388-020-01517-3. Epub 2020 Nov 4. PMID: 33149280. PMCID: PMC8275353.
38. Patel A, Iyer P, Matsuzaki S, Matsuo K, Sood AK, Fleming ND. **Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer.** Cancers (Basel). 2021 Feb 5;13(4):626. doi: 10.3390/cancers13040626. PMID: 33562443. Review. PMCID: PMC7915369.

39. Saha B, Mathur T, Tronolone JJ, Chokshi M, Lokhande GK, Selahi A, Gaharwar AK, Afshar-Kharghan V, Sood AK, Bao G, Jain A. **Human tumor microenvironment chip evaluates the consequences of platelet extravasation and combinatorial antitumor-antiplatelet therapy in ovarian cancer.** *Sci Adv.* 2021 Jul 21;7(30):eabg5283. doi: 10.1126/sciadv.abg5283. Print 2021 Jul. PMID: 34290095. PMCID: PMC8294767.
40. Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA, Hendrix MJC. **Editor's Note: The Paradoxical Expression of *Masp1* in Ovarian Carcinoma.** *Clin Cancer Res.* 2021 Aug 1;27(15):4456. doi: 10.1158/1078-0432.CCR-21-2122. PMID: 34341061.
41. Virani S, Baiocchi G, Bowtell D, Cabasag CJ, Cho KR, Fortner RT, Fujiwara K, Kim JW, Köbel M, Kurtz JE, Levine DA, Menon U, Norquist BM, Pharoah PDP, Sood AK, Tworoger ST, Wentzensen N, Chanock SJ, Brennan P, Trabert B. **Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research.** *Carcinogenesis.* 2021 Jun 21;42(6):785-793. doi: 10.1093/carcin/bgab043. PMID: 34037709.
42. Zhong Y, Liu J, Li X, Westin SN, Malpica A, Lawson BC, Lee S, Fellman BM, Coleman RL, Sood AK, Fleming ND. **A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy.** *Cancers (Basel).* 2021 Feb 9;13(4):704. doi: 10.3390/cancers13040704. PMID: 33572451. PMCID: PMC7916221.
43. Zhu Y, Ferri-Borgogno S, Sheng J, Yeung TL, Burks JK, Cappello P, Jazaeri AA, Kim JH, Han GH, Birrer MJ, Mok SC, Wong STC. **SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment.** *Cancers (Basel).* 2021 Apr 8;13(8):1777. doi: 10.3390/cancers13081777. PMID: 33917869. PMCID: PMC8068305.